Lung Cancer Surgery Enters Evidence Driven Era

Lung cancer surgery is undergoing a decisive transformation, with 2024–2025 bringing unprecedented advances in robotic-assisted procedures, targeted therapies, and optimized surgical timing. Breakthroughs such as the world’s first fully robotic double-lung transplant, exceptional drug response rates in advanced cases, and five-year survival gains from integrated immunotherapy are redefining treatment standards. This evidence-driven momentum is pushing health systems, device makers, and pharmaceutical innovators to align technology adoption and care pathways more closely with proven clinical outcomes. 

Latest developments (2024–2025)

• Robotic lung transplantation and minimally invasive transplants. NYU Langone reported the world’s first fully robotic double-lung transplant on Oct 22, 2024, using a da Vinci Xi robotic platform; the patient was discharged and reported markedly improved breathing after the procedure. Cleveland Clinic Abu Dhabi performed the Gulf region’s first robotic lung transplant in July 2025 and stated it is “one of the five centers in the world to have performed this surgery,” this landmark procedure brings the total to two patients who have successfully received robotic lung transplants, representing a significant milestone in the region’s advancement of complex surgery and organ transplantation.

• Targeted systemic therapy showing unprecedented responses. At the American Association for Cancer Research meeting in Chicago, researchers reported that an experimental Boehringer Ingelheim drug delivered “unprecedented” benefits for patients with advanced lung cancer who had previously undergone other treatments. Among 75 patients with previously treated non-small cell lung cancer (NSCLC) carrying HER2 tyrosine kinase domain (TKD) mutations, 71% experienced substantial tumor reduction while receiving zongertinib. NSCLC remains the most prevalent form of lung cancer.

• Surgical timing and long-term survival evidence. In the CheckMate-816 clinical trial, 358 patients with stage 1B to 3A resectable NSCLC were randomly assigned to undergo three cycles of standard chemotherapy, either alone or in combination with the anti-PD-1 immunotherapy drug nivolumab, before proceeding to surgery. In the group receiving immunotherapy combined with chemotherapy, 24% of patients achieved complete remission, with no remaining tumor detected in the lungs or lymph nodes after surgery. Among those with complete cancer clearance at the time of surgery, the five-year survival rate reached 95%.

FDA Approved Cancer Treatments

Alectinib: On April 18, the Food and Drug Administration (FDA) granted approval for alectinib as an adjuvant treatment for patients with ALK-positive NSCLC, following the results of the ALINA trial.
Rybrevant plus Lazcluze: The FDA has authorized the use of Rybrevant in combination with Lazcluze as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer.
Imfinzi for Limited-Stage Small Cell Lung Cancer: Imfinzi (durvalumab) received approval for use in adults with limited-stage small cell lung cancer whose disease has not progressed after receiving concurrent platinum-based chemotherapy and radiation therapy.

Regional Analysis

Key Players

• NYU Langone – Performed the world’s first fully robotic double-lung transplant on October 22, 2024, using the da Vinci Xi robotic platform; patient discharged with markedly improved breathing post-procedure.

• Cleveland Clinic Abu Dhabi – Conducted the Gulf region’s first robotic lung transplant in July 2025; recognized as one of only five centers worldwide to have performed this surgery.

• Boehringer Ingelheim – Developer of the experimental drug zongertinib, which showed “unprecedented” benefits in advanced NSCLC patients with HER2 tyrosine kinase domain (TKD) mutations, achieving a 71% substantial tumor reduction rate in a 75-patient cohort.

• CheckMate-816 Clinical Trial Investigators – Evaluated nivolumab combined with standard chemotherapy in resectable stage 1B–3A NSCLC; achieved 24% complete remission rates prior to surgery, with 95% five-year survival among those with complete cancer clearance.

Other Key Players: Medtronic, Siemens Healthineers AG, Accuray Incorporated, Karl Storz Se & Co. KG, Olympus Corporation.
 

Conclusion:

Lung cancer surgery is undergoing a transformative shift, driven by landmark advancements in robotic-assisted procedures, precision drug therapies, and optimized surgical timing. These innovations are setting new benchmarks for survival outcomes, reducing recovery times, and expanding treatment possibilities for patients previously considered inoperable. As evidence accumulates, the alignment of technology, systemic therapy, and perioperative care with reimbursement and clinical guidelines will be crucial for healthcare systems and industry stakeholders. The momentum built in 2024–2025 suggests a future where lung cancer surgery is not only more effective but also more patient-centric, with global collaboration accelerating the translation of breakthroughs into everyday practice.

About Next Move Strategy Consulting:

Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analysed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes Next Move different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations with industry experts across a diverse range of industry sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical business decisions that enables them to move beyond time and have competitive edge in the industry.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

For more information, please contact:

Next Move Strategy Consulting

5th Floor 867

Boylston St, STE 500,

Boston, MA 02116, U.S.

E-Mail: [email protected]

Direct: +18577585017

Website: www.nextmsc.com